Prognostic Value of Apoptosis-Regulating Protein Expression in Anal Squamous Cell Carcinoma

Clinical Cancer Research

Volumn 9, Issue 17, 2003, Pages 6489-6496

  Allal, Abdelkarim S ^a   Waelchli, Laurent ^a   Bründler, Marie Anne ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS REGULATING PROTEIN; CELL PROTEIN; FLUOROURACIL; MITOMYCIN C; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANUS CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECTUM BIOPSY; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANUS NEOPLASMS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0348223928     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. UKCCCR Anal Cancer Trial Working Party. Epidermoid anal cancer. Results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5 fluorouracil and mitomycin C. Lancet, 348: 1049-1054, 1996.
2. Allal, A. S., Mermillod, B., Roth, A. D., Marti, M. C., and Kurtz, J. M. The impact of treatment factors on local control in T2-T3 anal carcinomas treated with radiotherapy with or without chemotherapy. Cancer, 79: 2329-2335, 1997.
3. Bartelink, H., Roelofsen, F., Eschwege, F., Rougier, P., Bosset, J. F., Gonzalez, G. Peiffert D., van Glabbeke, M., and Pierart, M. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal canal cancer. J. Clin. Oncol., 5: 2040-2049, 1997.
4. Allal, A. S., Sprangers, M. A. G., Laurencet, F., Reymond, M. A., and Kurtz, J. M. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. Br. J. Cancer, 80: 1588-1594, 1999.
5. Allal, A. S., Laurencet, F. M., Reymond, M. A., Kurtz, J. M., and Marti, M-C. Effectiveness of surgical salvage therapy for locally uncontrolled anal carcinoma after sphincter-conserving treatment. Cancer (Phila.), 86: 405-409, 1999.
6. Lowe, S. W., and Lin, A. W. Apoptosis in cancer. Carcinogenesis (Lond.), 21: 485-495, 2000.
7. Rupnow, B. A., Murtha, A. D., Alarcon, R. M., Giaccia, A. J., and Knox, S. J. Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Cancer Res., 58: 1779-1784, 1998.
8. Steel, G. G. The case against apoptosis. Acta. Oncol., 40: 968-975, 2001.
9. Green, D. R. Apoptotic pathways: paper wraps stone blunts scissors. Cell. 102: 1-4, 2000.
10. Adams, J. M., and Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science (Wash. DC), 281: 1322-1326, 1998.
11. Kim, J. Y., Cho, H. Y., Lee, K. C., Hwang, Y. J., Lee, M. H., Roberts, S. A., and Kim C. H. Tumor apoptosis in cervical cancer: its role as a prognostic factor in 42 radiotherapy patients. Int. J. Cancer, 96: 305-312, 2000.
12. Levine, E. L., Renehan, A., Gossiel, R., Davidson, S. E., Roberts, S. A., Chadwick, C., Wilks, D. P., Potten, C. S., Hendry, J. H., Hunter, R. D., et al. Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother. Oncol., 37: 1-9, 1995.
13. Komaki, R., Fujii, T., Perkins, P., Ro, J. Y., Allen, P. K., Mason, K. A., Mountain, C. F., and Milas, L. Apoptosis and mitosis as prognostic factors in pathologically staged N1 non small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 36: 601-605, 1996.
14. Tjalma, W. A., Weyler, J. J., Bogers, J. J., Pollefliet, C., Baay, M., Goovaerts, G. C., Vermorken, J. B., van Dam, P. A., van Marck, E. A., and Buytaert, P. M. The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. Eur. J. Obstet. Gynecol. Reprod. Biol., 97: 223-230, 2001.
15. Schwandner, O., Schiedeck, T. H., Bruch, H. P., Duchrow, M., Windhoevel, U., and Broll, R. p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer. Eur. J. Cancer, 36: 348-536, 2000.
16. Baekelandt, M., Holm, R., Nesland, J. M., Trope, C. G., and Kristensen, G. B. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J. Clin. Oncol., 18: 3775-3781, 2000.
17. Ong, F., Moonen, L. M., Gallee, M. P., ten Bosch, C., Zerp, S. F., Hart, A. A., Bartelink, H., and Verheij, M. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother. Oncol., 61: 169-175, 2001.
18. Pollack, I. F., Finkelstein, S. D., Woods, J., Burnham, J., Holmes, E. J., Hamilton, R. L., Yates, A. J., Boyett, J. M., Finlay, J. L., and Sposto, R. ; The Children's Cancer Group. Expression of p53 and prognosis in children with malignant gliomas. N. Eng. J. Med., 346: 420-427, 2002.
19. Bonin, S. R., Pajak, T. F., Russell, A. H., Coia, L. R., Paris, K. J., Flam, M. S., and Sauter, E. R. Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. Radiation Therapy Oncology Group. Cancer (Phila.), 85: 1226-1233, 1999.
20. Wong, C. S., Tsao, M. S., Sharma, V., Chapman, W. B., Pintilie, M., and Cummings, B. J. Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal. Int. J. Radiat. Oncol. Biol. Phys., 45: 309-314, 1999.
21. Leers, M. P., Kolgen, W., Bjorklund, V., Bergman, T., Tribbick, G., and Persson, B. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol., 187: 567-572, 1999.
22. Reed, J. C. Bcl-2 family proteins: regulators of chemoresistance in cancer. Toxicol. Lett., 82-83: 155-158, 1995.
23. Johnstone, R. W., Ruefli, A. A., and Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell, 108: 1531-1564, 2002.
24. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
25. Strasser, A., Harris, A. W., Jacks, T., and Cory, S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell, 79: 329-339, 1994.
26. Kerr, J. F., Winterford, C. M., and Harmon, B. V. Apoptosis. Its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.
27. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., and Giaccia, A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond.), 379: 88-91, 1996.
28. Sheridan, M. T., Cooper, R. A., and West, C. M. A high ratio of apoptosis to proliferation correlates with improved survival after radiotherapy for cervical adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys., 44: 507-512, 1999.
29. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
30. Jakate, S. M., and Saclarides, T. J. Immunohistochemical detection of mutant P53 protein and human papillomavirus-related E6 protein in anal cancers. Dis. Colon. Rectum., 36: 1026-1029, 1993.
31. Gannon, J. V., Greaves, R., Iggo, R., and Lane, D. P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J., 9: 1595-1602, 1990.
32. Ahomadegbe, J. C., Barrois, M., Fogel, S., Le Bihan, M. L., Douc-Rasy, S., Duvillard, P., Armand, J. P., and Riou, G. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene, 10: 1217-1227, 1995.
33. Jurgensmeier, J. M., Xie, Z., Deveraux, Q., Ellerby, L., Bredesen, D., and Reed, J. C. Bax directly induces release of cytochrome c from isolated mitochondria. Proc. Natl. Acad. Sci. USA, 95: 4997-5002, 1998.
34. Xie, X., Clausen, O. P., De Angelis, P., and Boysen, M. Bax expression has prognostic significance that is enhanced when combined with AgNOR counts in glottic carcinomas. Br. J. Cancer, 78: 100-105, 1998.
35. Tai, Y. T., Lee, S., Niloff, E., Weisman, C., Strobel, T., and Cannistra, S. A. BAX protein expression and clinical outcome in epithelial ovarian cancer. J. Clin. Oncol., 16: 2583-2590, 1998.
36. Crawford, R. A., Caldwell, C., Iles, R. K., Lowe, D., Shepherd, J. H., and Chard, T. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. Br. J. Cancer, 78: 210-214, 1998.
37. Harima, Y., Nagata, K., Harima, K., Oka, A., Ostapenko, V. V., Shikata, N., Ohnishi, T., and Tanaka, Y. Bax and Bcl-2 protein expression following radiation therapy versus radiation plus thermoradiotherapy in stage IIIB cervical carcinoma. Cancer (Phila.), 88: 132-138, 2000.
38. Reed, J. C. Dysregulation of apoptosis in cancer. J. Clin. Oncol., 17: 2941-2953, 1999.
39. Robertson, L. E., Plunkett, W., McConnell, K., Keating, M. J., and McDonnell, T. J. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia (Baltimore), 10: 456-459, 1996.
40. Rantanen, S., Monni, O., Joensuu, H., Franssila, K., and Knuutila, S. Causes and consequences of BCL2 overexpression in diffuse large B-cell lymphoma. Leuk. Lymphoma., 42: 1089-1098, 2001.
41. Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., Boracchi, P., Mezzetti, M., Di Fronzo, G., Rilke, F., and Veronesi, U. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer. Inst. (Bethesda), 86: 499-504, 1994.
42. Pezzella, F., Turley, H., Kuzu, I., Tungekar, M. F., Dunnill, M. S., Pierce, C. B., Harris, A., Gatter, K. C., and Mason, D. Y. bcl-2 protein in non-small-cell lung carcinoma. N. Engl. J. Med., 329: 690-694, 1993.
43. Monni, O., Joensuu, H., Franssila, K., Klefstrom, J., Alitalo, K., and Knuutila, S. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood, 90: 1168-1174, 1997.
44. Shinoura, N., Yoshida, Y., Nishimura, M., Muramatsu, Y., Asai, A., Kirino, T., and Hamada, H. Expression level of Bcl-2 determines antior proapoptotic function. Cancer Res., 59: 4119-4128, 1999.
45. Miyashita, T., Kitada, S., Krajewski, S., Horne, W. A., Delia, D., and Reed, J. C. Overexpression of the Bcl-2 protein increases the half-life of p21Bax. J. Biol. Chem., 270: 26049-26052, 1995.
46. Koukourakis, M. I., Giatromanolaki, A., O'Byrne, K. J., Whitehouse, R. M., Talbot, D. C., Gatter, K. C., and Harris, A. L. Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. Int. J. Cancer, 74: 565-570, 1997.
47. Zhou, P., Qian, L., Kozopas, K. M., and Craig, R. W. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood, 89: 630-643, 1997.
48. Kitada, S., Andersen, J., Akar, S., Zapata, J. M., Takayama, S., Krajewski, S., Wang, H. G., Zhang, X., Bullrich, F., Croce, C. M., and et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood, 91: 3379-3389, 1998.
49. Baekelandt, M., Kristensen, G. B., Nesland, J. M., Trope, C. G., and Holm, R. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J. Clin. Oncol., 17: 2061-2068, 1999.
50. Uchida, T., Minei, S., Gao, J. P., Wang, C., Satoh, T., and Baba, S. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder. Oncol. Rep., 9: 253-259, 2002.